Andrew Weiss News
-
Newron Pharmaceuticals SpA, an Italian developer of an experimental treatment for Parkinson’s disease, rose to the highest in almost six weeks after saying the drug succeeded in two clinical trials.
-
Malcolm has $30 billion, a passion for steaks, and a plan to buy 3 billion steaks for $10 each on his next birthday.
-
Novartis AG shareholders, disappointed with the company’s track record on acquisitions, are urging the new chairman to tear up some of the deals Daniel Vasella engineered in almost two decades building Europe’s largest drugmaker.
-
Novartis AG wants patients to stop taking one of its best-selling drugs.
-
Roche Holding AG delayed development of the experimental diabetes drug taspoglutide by at least 12 to 18 months after more people than expected suffered from side effects such as skin reactions and digestive symptoms.
-
Novartis AG said that an experimental antibody relieved pain and stopped new attacks of gout better than a steroid injection in two advanced studies.
-
Novartis AG indicated Alcon Inc. shareholders should take another look at its $11.5 billion buyout offer now that an increase in the Swiss drugmaker’s share price and a rally in the franc have lifted the value of the bid.
-
Roche Holding AG’s failure to persuade a U.S. panel to back Avastin in breast cancer is the third such loss for the Swiss drugmaker as it looks for new ways to expand sales of the world’s top-selling cancer medicine.
-
Illumina Inc., the U.S. maker of gene-mapping tools, rose above Roche Holding AG’s increased hostile takeover bid, indicating investors are betting that an even higher offer will come.
-
Actelion Ltd. climbed the most in more than five months after the Swiss maker of the Tracleer lung drug reiterated its forecast for 2013.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page